Novel small molecule inhibitors of the transcription factor ETS-1 and their antitumor activity against hepatocellular carcinoma

被引:21
作者
Jie, Yamin [1 ]
Liu, Guijun [2 ]
Mingyan, E. [3 ]
Li, Ying [4 ]
Xu, Guo [1 ]
Guo, Jingjing [5 ]
Li, Yinyin [6 ]
Rong, Guanghua [7 ]
Li, Yongwu [8 ]
Gu, Anxin [3 ]
机构
[1] Harbin Med Univ, Dept Radiat Oncol, Affiliated Hosp 4, Harbin 150001, Heilongjiang, Peoples R China
[2] Heilongjiang Univ Chinese Med Harbin, Affiliated Hosp 2, Harbin 150040, Heilongjiang, Peoples R China
[3] Harbin Med Univ, Canc Hosp, Dept Radiat Oncol, Harbin 150040, Heilongjiang, Peoples R China
[4] Harbin Med Univ, Inst Hard Tissue Dev & Regenerat, Affiliated Hosp 2, Harbin 150001, Heilongjiang, Peoples R China
[5] Chinese Peoples Liberat Army Gen Hosp, Dept Out Patient Clin, Med Ctr 1, Beijing 100853, Peoples R China
[6] Peoples Liberat Army Gen Hosp, Dept Liver Dis, Med Ctr 5, Beijing 100039, Peoples R China
[7] Peoples Liberat Army Gen Hosp, Dept Oncol, Med Ctr 5, Beijing 100039, Peoples R China
[8] Peoples Liberat Army Gen Hosp, Dept Radiol, Med Ctr 5, Beijing 100039, Peoples R China
关键词
Hepatocellular carcinoma; E26 transformation specific sequence 1; Small molecular inhibitor; Matrix metalloproteinase; SORAFENIB; CELLS; SENSITIVITY; ACTIVATION; INVASION; APATINIB;
D O I
10.1016/j.ejphar.2021.174214
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The transcription factor ETS-1 (E26 transformation specific sequence 1) is the key regulator for malignant tumor cell proliferation and invasion by mediating the transcription of the invasion/migration related factors, e.g. MMPs (matrix metalloproteinases). This work aims to identify the novel small molecule inhibitors of ETS-1 using a small molecule compound library and to study the inhibitors' antitumor activity against hepatocellular carcinoma (HCC). The luciferase reporter is used to examine the inhibition and activation of ETS-1's transcription factor activity in HCC cells, including a highly invasive HCC cell line, MHCC97-H, and five lines of patient-derived cells. The inhibition of the proliferation of HCC cells is examined using the MTT assay, while the invasion of HCC cells is examined using the transwell assay. The anti-tumor activity of the selected compound on HCC cells is also examined in a subcutaneous tumor model or intrahepatic tumor model in nude mice. The results show that for the first time, four compounds, EI1 similar to EI-4, can inhibit the transcription factor activation of ETS-1 and the proliferation or invasion of HCC cells. Among the four compounds, EI-4 has the best activation. The results from this paper contribute to expanding our understanding of ETS-1 and provide alternative, the safer and more effective, HCC molecular therapy strategies.
引用
收藏
页数:11
相关论文
共 41 条
[1]   TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR [J].
Bhagyaraj, Ella ;
Ahuja, Nancy ;
Kumar, Sumit ;
Tiwari, Drishti ;
Gupta, Shalini ;
Nanduri, Ravikanth ;
Gupta, Pawan .
CELL CYCLE, 2019, 18 (24) :3589-3602
[2]   Neratinib decreases pro-survival responses of [sorafenib plus vorinostat] in pancreatic cancer [J].
Booth, Laurence ;
Poklepovic, Andrew ;
Dent, Paul .
BIOCHEMICAL PHARMACOLOGY, 2020, 178
[3]   TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer [J].
Breunig, Christian ;
Erdem, Nese ;
Bott, Alexander ;
Greiwe, Julia F. ;
Reinz, Eileen ;
Bernhardt, Stephan ;
Giacomelli, Chiara ;
Wachter, Astrid ;
Kanthelhardt, Eva J. ;
Beissbarth, Tim ;
Vetter, Martina ;
Wiemann, Stefan .
MOLECULAR ONCOLOGY, 2018, 12 (09) :1447-1463
[4]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[5]   What intervention regimen is most effective prevention for Portal venous system thrombosis after splenectomy in cirrhotics patients with Portal hypertension? Systematic review and network meta-analysis [J].
Ding, Hongda ;
Zhang, Yingshi ;
Zhao, Liang ;
Wu, Si ;
Liu, Junpeng ;
Wang, Caibin ;
Pei, Tong ;
Su, Yang .
PHARMACOLOGICAL RESEARCH, 2020, 157
[6]   Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo [J].
Du, Guifang ;
Wang, Jing ;
Zhang, Ting ;
Ding, Qiang ;
Jia, Xiaodong ;
Zhao, Xueke ;
Dong, Jinke ;
Yang, Xinrui ;
Lu, Shanshan ;
Zhang, Cuihong ;
Liu, Ze ;
Zeng, Zhen ;
Safadi, Rifaat ;
Qi, Ruizhao ;
Zhao, Xin ;
Hong, Zhixian ;
Lu, Yinying .
CELL DEATH & DISEASE, 2020, 11 (02)
[7]   Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents [J].
Feng, Ying-Qi ;
Li, Bo-An ;
Feng, Fan ;
Chen, Yong-Shou ;
Ren, Yi-Xin ;
Zhang, Heng ;
Cao, Shuang .
ONCOTARGETS AND THERAPY, 2020, 13 :7165-7176
[8]   Virtual Screening and Optimization of Novel mTOR Inhibitors for Radiosensitization of Hepatocellular Carcinoma [J].
Feng, Ying-Qi ;
Gu, Shuang-Xi ;
Chen, Yong-Shou ;
Gao, Xu-Dong ;
Ren, Yi-Xin ;
Chen, Jian-Chao ;
Lu, Yin-Ying ;
Zhang, Heng ;
Cao, Shuang .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 :1779-1798
[9]   Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression [J].
Fu, Rongdang ;
Jiang, Shaotao ;
Li, Jieyuan ;
Chen, Huanwei ;
Zhang, Xiaohong .
MEDICAL ONCOLOGY, 2020, 37 (04)
[10]   ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance [J].
Gao, Xudong ;
Chen, Hebing ;
Huang, Xin ;
Li, Hao ;
Liu, Zhen ;
Bo, Xiaochen .
ONCOTARGETS AND THERAPY, 2019, 12 :1629-1640